The Cellular Immunotherapy of Cancer study section will focus on the many approaches to cellular therapy, including stem cell transplantation, adoptive cellular therapies and their toxicities, as well as therapeutic combinations that employ adoptive and allogeneic cell transfer.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.

Topics


  • Hematopoietic stem cell transplantation (allogeneic, autologous).
  • Adoptive cellular therapies (TILs, CAR- and TCR-engineered T cells, NK/NKT cells) using immune cells as cancer treatment.
  • Associated immune toxicities including graft-versus-host disease and cytokine release syndrome.
  • Cellular therapies including dendritic cells and mononuclear phagocytes.
  • Combination therapies that contain cell therapies

Shared Interests and Overlaps

There are shared interests with Transplantation, Tolerance and Tumor Immunology (TTT) in transplantation and graft vs. host disease.  Applications that focus on the basic transplantation immunology and immune mechanism of development and strategies for prevention of graft vs. host disease may be reviewed in TTT; applications that include the promotion of graft vs. tumor effects may also be reviewed in TTT. Applications that focus on the hematopoietic stem cell transplantation as a part of cancer treatment and the immune toxicities associated with graft vs host disease may be reviewed in CIC.

There are shared interests with Clinical Oncology (CONC) in the area of adaptive cellular therapies. Applications that focus on the cellular immunotherapy clinical trials and correlative studies may be reviewed in CONC. Applications that focus on involving preclinical cellular immunotherapy and combination with immunotherapy/chemotherapy may be reviewed in CIC.

There are shared interests with Translational Immuno-Oncology (TIO) study section in antibodies engineering such as single chain Fc for cancer therapy. Applications that focus on using the engineered antibody as standalone or combined with other therapeutics may be reviewed in TIO. Applications that focus on engineering the antibody for generating CAR-T cells and evaluation of their antitumor effects may be reviewed in CIC.

There are shared interests with Therapeutic Immune Regulation (TIR) in the areas of therapeutic responses and combination therapies for cancer. Applications that focus on mechanisms of tumor resistance to cellular therapies such as CAR-T cells may be reviewed in TIR. Applications that focus on developing CAR-T and other cellular therapies and evaluating their antitumor effects and associated toxicities may be reviewed in CIC.

There are shared interests with Clinical Neuroimmunology and Brain Tumors (CNBT) in the areas of neural and brain tumors.   Applications focused on immunological aspects of neural tissues and diseases unrelated to tumors may be reviewed in CNBT. Applications studying the immunopathology and immunotherapy of central nervous system tumors (glioma, medulloblastoma, etc.) may be reviewed in either CNBT or CIC (if focus is on cellular therapies).

 

Last updated: 01/16/2024 05:10